Loading market data...
GrantExec
GrantExec

Questions? Contact Us

Β© 2025 GrantExec. All rights reserved.

Forecast to Publish a Notice of Funding Opportunity for The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)

This funding opportunity supports academic organizations in conducting early-phase clinical trials for new cancer treatments while mentoring emerging researchers in the field.

$12,000,000
Forecasted
Nationwide
Grant Description

The National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), under the Department of Health and Human Services, intends to release a Notice of Funding Opportunity (NOFO) in the summer of 2025. This initiative seeks applications for the establishment or maintenance of Lead Academic Organizations (LAOs) as part of the Experimental Therapeutics Clinical Trials Network (ETCTN). The opportunity is issued as a forecast under the funding opportunity number FOR-CA-25-089 and is classified as a discretionary cooperative agreement under the UM1 Clinical Trial Required activity code. The purpose of this funding is to support LAOs in designing, developing, monitoring, conducting, and analyzing early-phase clinical trials. These trials will involve experimental therapeutic agents under New Investigational Drug (IND) applications for which the NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP), holds regulatory sponsorship. LAOs are expected to engage not only in trials they lead but also in those led by other organizations within the ETCTN network. In addition to conducting trials, each LAO will oversee scientific, programmatic, financial, and administrative aspects for participating sites. Another critical component of the role includes providing mentorship to early-career investigators, fostering the development of future leaders in clinical trial research. The use of the ETCTN Pharmacokinetic (PK) Resource Laboratory is mandatory for all LAOs to conduct pharmacokinetic studies, analyze drug interactions, pharmacodynamics, and related factors. This laboratory is funded through a separate opportunity (RFA-CA-25-027). Currently, applications are not being accepted; this forecast serves to give potential applicants ample preparation time to form collaborations and develop responsive proposals. The official NOFO is projected to be released by July 31, 2025, with an expected application due date of October 30, 2025. Awards are anticipated to be announced by July 1, 2026, with the project start date set for the same day. The total estimated program funding is $12 million, and approximately six awards are expected. Eligible applicants include private institutions of higher education, public and state-controlled institutions of higher education, and nonprofit organizations with 501(c)(3) status. Interested parties are encouraged to begin preparing in advance. For further details or inquiries, applicants may contact Lori A. Henderson, Ph.D., at the NCI by phone at 240-276-5930 or via email at NCIETCTNRFA@mail.nih.gov.

Funding Details

Award Range

Not specified - Not specified

Total Program Funding

$12,000,000

Number of Awards

6

Matching Requirement

No

Additional Details

Funding will support approximately six awards for institutions to conduct early-phase clinical trials. Use of a specific pharmacokinetic lab is mandated. Funding supports scientific, administrative, and mentorship responsibilities.

Eligibility

Eligible Applicants

Public and State controlled institutions of higher education
Nonprofits
Private institutions of higher education

Geographic Eligibility

All

Key Dates

Application Opens

July 31, 2025

Application Closes

October 30, 2025

Contact Information

Grantor

Lori A. Henderson

Subscribe to view contact details

Newsletter Required
Categories
Health